Medtronic Plc. · NYSE:MDT
Medtronic — 42nd Annual J.P. Morgan Healthcare Conference (January 2024)
15 slides from Medtronic's conference presentation, Jan 8, 2024
Slide 1: 42nd annual J.P. Morgan healthcare conference
42nd annual J.P. Morgan healthcare conference Management Attendees: Geoff Martha, Chairman and CEO Karen Parkhill, EVP and CFO Que Dallara, EVP and President, Diabetes Mike Marinaro, EVP and President, Surgical Sean Salmon, EVP and President, Cardiovascular Brett Wall, EVP and President, Neuroscienc
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the developme
Slide 3: Delivering on FY24 commitments
Delivering on FY24 commitments Building track record of consistency; strong cadence of innovative product approvals Leading positions across large secular growth markets amplified by latest game-changing innovative approvals • Delivering mid-single digit organic revenue growth, driven by meaningful
Slide 4: Combined portfolio is increasingly well-positioned to deliver growth
Combined portfolio is increasingly well-positioned to deliver growth Confidence to deliver long-term mid-single digit organic revenue growth in-line with end markets ANNOUNCED Market Share DIVESTITURES Growth Position Recent Approvals Patient Monitoring Respiratory Interventions Other • Evolut™ FX T
Slide 5: Cardiac Ablation | Poised to expand share in underpenetrated, attractive EP space
Cardiac Ablation | Poised to expand share in underpenetrated, attractive EP space Innovation in Cryo, PFA, and Mapping to strengthen competitiveness in both single shot and focal segments OPPORTUNITY $8B+ Affera™ Mapping & Ablation System PulseSelect™ PFA System EP market today – LDD CAGR Single Sho
Slide 6: Diabetes | Returning to growth as Smart Dosing overtakes current therapies
Diabetes | Returning to growth as Smart Dosing overtakes current therapies Only company investing in a complete ecosystem of differentiated technology for Intensive Insulin patient population OPPORTUNITY ~7.1M CE Mark T1/T2 Intensive Insulin ~6.7M $14B+ Approval patient therapy mix patients patients
Slide 7: Structural Heart | Positioned to execute on significant TAVR and M&T opportunity
Structural Heart | Positioned to execute on significant TAVR and M&T opportunity Large, HSD to LDD growth TAVR segment with additional investments in rapidly-growing Mitral & Tricuspid OPPORTUNITY $6B+ Evolut Low Risk 4-year Data TAVR segment today: HSD to LDD CAGR All-Cause Mortality and Disabling
Slide 8: Synergistic Businesses | Leveraging technology, channel and infrastructure
Synergistic Businesses | Leveraging technology, channel and infrastructure Meaningful innovation with transformative opportunity for interventional and diagnostic procedures ENT Cardiac Surgery Neuromodulation Endoscopy FDA GI Genius™ Approval Intelligent AI-enabled Breaking Endoscopy Module Penditu
Slide 9: Established Market Leaders | Leading positions in largest businesses
Established Market Leaders | Leading positions in largest businesses Continued innovation extending advantages and generating attractive higher-margin growth Cardiac Rhythm Management Cranial & Spinal Technologies Surgical AiBLE™ • Aurora EV-ICD™ U.S. & WE Spinal Digital • Attractive growth profile
Slide 10: Renal Denervation | Symplicity Spyral revolutionary hypertension treatment
Renal Denervation | Symplicity Spyral™ revolutionary hypertension treatment Hypertension is the leading modifiable cause of heart attack, stroke, and death; Despite medication, control rates remain low OPPORTUNITY Significant, safe, and sustained 1 Billion + blood pressure reductions 4 random contro
Slide 11: Extensive transformation to improve durability of our growth
Extensive transformation to improve durability of our growth Foundational changes driving improved performance; supports leveraged earnings growth over time Impactful Changes Expected Benefits ✓ Changed operating model by removing group structure and empowering individual businesses Durable revenue
Slide 12: Operations & Supply Chain | Significant opportunities for cost savings over time
Operations & Supply Chain | Significant opportunities for cost savings over time Increasing confidence to deliver consistent cost out in excess of inflation to help enable gross margin improvement Automation & Digitalization Minimize human touch points & real time analytics Supplier Performance 28 a
Slide 13: Engineering AI Solutions | Transforming how we deliver innovation
Engineering AI Solutions | Transforming how we deliver innovation AI Center of Excellence driving a cohesive and purposeful strategy to advance our leadership position in AI-enabled care Harnessing the power of AI today Uniquely positioned to advance AI; Clinical decision support | New indications |
Slide 14: Recent approvals and launches drive confidence in near-term revenue growth
Recent approvals and launches drive confidence in near-term revenue growth Continued advancements and disruptions to fuel growth and share gain/recapture across our Portfolios Cardiovascular Medical Surgical Neuroscience Diabetes Evolut™ FX AiBLE™ TAVR System MiniMed™ 780G system with Aurora EV-ICD™
Slide 15: Becoming a mission-driven AND performance-driven culture
Becoming a mission-driven AND performance-driven culture Several recent meaningful approvals | Deliver durable growth | Improving earnings power to create shareholder value & 15 42nd annual J.P. Morgan healthcare conference | January 8, 2024
Medtronic — 42nd Annual J.P. Morgan Healthcare Conference (January 2024) on 6ix